Abstract: Medicinal fluid delivery devices and methods for advancing and retracting needles are disclosed. According to an aspect, a medicinal fluid delivery device includes a tube that defines an interior space that extends between a first and second openings. The device includes a needle including a proximal end and a distal end that substantially align in a first direction. A portion of the distal end is biased to extend in a second direction different than the first direction. A mechanism is attached to the proximal end and configured to position the distal end between a first position and a second position. In the first position, the portion of the distal end is constrained by the interior wall such that is does not extend in the second direction. In the second position, the distal end is not constrained by the interior wall such that it extends in the second direction.

Abstract: The present disclosure methods and kits for use of stimulator of interferon genes (STING) agonist compounds, such as cyclic dinucleotides, amidobenzimidazoles, and benzothiophenes, in the treatment and prevention of pain, such as neuropathic pain, inflammatory pain, and cancer pain. Combination therapies and pharmaceutical formulations for treating of pain are also described.

Abstract: A special-shaped plane reflecting mirror including a first reflecting mirror, a second reflecting mirror, a third reflecting mirror, a fourth reflecting mirror and a fifth reflecting mirror; wherein the second reflecting mirror and the fourth reflecting mirror are constructed the same and symmetrically arranged on both sides of the first reflecting mirror, the third and fifth reflecting mirrors have the same structure and are arranged symmetrically on both sides of the first reflecting mirror, the first reflecting mirror is placed at an angle of 45° with the horizontal plane, and the second reflecting mirror. The first mirror is placed at an angle of 45° with the horizontal plane, the angle between the reflection surface of the second mirror and the reflection surface of the first mirror is 165°, and the angle between the reflection surface of the third mirror and the reflection surface of the first mirror is 163°.

Abstract: Methods for treating conditions including itch and pain are described. The methods include administering a therapeutically effective amount of an N-substituted indole Nav1.7 inhibitor to a subject in need thereof. New N-substituted indole compounds, useful as Nav1.7 inhibitors for the treatment of itch and/or pain are also provided, as well as pharmaceutical compositions containing the Nav1.7 inhibitors.

Abstract: Certain embodiments provide an isolated anti-matrix metalloproteinase-9 (MMP-9) antibody or fragment thereof, as well as methods of use thereof.

Abstract: The present disclosure describes, in part, compositions and methods for treating pathologic pains associated with malignant growth disorders by administering a therapeutically effective amount of K+/Cl-cotransporter (Kcc2/KCC2) gene expression enhancer to a subject in need.

Abstract: Disclosed herein are bone marrow stromal cells. The bone marrow stromal cells may express and/or secrete TGF-?1. The bone marrow stromal cells may express CXCR4. Also disclosed herein is a method of treating pain in a subject in need thereof. The method of treating may include administration of the bone marrow stromal cells to the subject. The pain may be neuropathic pain.

Abstract: A special-shaped plane reflecting mirror including a first reflecting mirror, a second reflecting mirror, a third reflecting mirror, a fourth reflecting mirror and a fifth reflecting mirror; wherein the second reflecting mirror and the fourth reflecting mirror are constructed the same and symmetrically arranged on both sides of the first reflecting mirror, the third and fifth reflecting mirrors have the same structure and are arranged symmetrically on both sides of the first reflecting mirror, the first reflecting mirror is placed at an angle of 45° with the horizontal plane, and the second reflecting mirror. The first mirror is placed at an angle of 45° with the horizontal plane, the angle between the reflection surface of the second mirror and the reflection surface of the first mirror is 165°, and the angle between the reflection surface of the third mirror and the reflection surface of the first mirror is 163°.

Abstract: Disclosed herein are bone marrow stromal cells. The bone marrow stromal cells may express and/or secrete TGF-?I. The bone marrow stromal cells may express CXCR4. Also disclosed herein is a method of treating pain in a subject in need thereof. The method of treating may include administration of the bone marrow stromal cells to the subject. The pain may be neuropathic pain.

Abstract: Disclosed herein are miR-711 inhibitors. The miR-711 inhibitors may disrupt the binding of miR-711 to TRPA1. Further provided are methods of treating a disease or condition in a subject, methods of inhibiting miR-711, and methods of inhibiting TRPA1 in a subject. The methods may include administering to the subject a miR-711 inhibitor.

Abstract: The present disclosure provides methods and kits for treating pain. More particularly, the present disclosure relates to methods of using PD-L1/PD-1-associated compounds to treat pain and/or bone destruction from bone cancer, and associated kits. The present disclosure also provides methods to assess the efficacy of compounds to suppress PD-1-associated nociceptive neuron activity.

Abstract: Disclosed herein are methods and compositions for treating a disease or disorder in a subject in need thereof. The methods may include administering to the subject a therapeutically effective amount of a GPR37 agonist. The disease or disorder may be selected from inflammation, inflammatory pain, chronic pain, viral infection, bacterial infection, malaria, sepsis, or a combination thereof.

Abstract: A method of treating pruritus (itching) in a subject in need thereof is carried out by administering the subject an active agent in a treatment effective amount, wherein the active agent is a superoxide dismuate (SOD) mimetic. The SOD mimetic can be a complex of a metal (e.g., manganese) and an organic ligand, with suitable organic ligands including porphyrins, polyamines, salens, nitroxides, and fullerenes. Compositions for carrying out such methods are also described.

Abstract: The present disclosure provides methods and kits for treating pain. More particularly, the present disclosure relates to methods of using PD-L1/PD-1-associated compounds to treat pain and/or bone destruction from bone cancer, and associated kits. The present disclosure also provides methods to assess the efficacy of compounds to suppress PD-1-associated nociceptive neuron activity.

Abstract: Medicinal fluid delivery devices and methods for advancing and retracting needles are disclosed. According to an aspect, a medicinal fluid delivery device includes a tube that defines an interior space that extends between a first and second openings. The device includes a needle including a proximal end and a distal end that substantially align in a first direction. A portion of the distal end is biased to extend in a second direction different than the first direction. A mechanism is attached to the proximal end and configured to position the distal end between a first position and a second position. In the first position, the portion of the distal end is constrained by the interior wall such that is does not extend in the second direction. In the second position, the distal end is not constrained by the interior wall such that it extends in the second direction.

Abstract: The present disclosure provides methods and kits for treating pain. More particularly, the present disclosure relates to methods of using PD-L1/PD-1-associated compounds to treat pain and/or bone destruction from bone cancer, and associated kits. The present disclosure also provides methods to assess the efficacy of compounds to suppress PD-1-associated nociceptive neuron activity.

Abstract: Disclosed herein are bone marrow stromal cells. The bone marrow stromal cells may express and/or secrete TGF-?I. The bone marrow stromal cells may express CXCR4. Also disclosed herein is a method of treating pain in a subject in need thereof. The method of treating may include administration of the bone marrow stromal cells to the subject. The pain may be neuropathic pain.

Abstract: Disclosed herein is an antibody that binds to a voltage sensor paddle (VSP) of Nav1.7. Also disclosed herein are methods of treating pain, itch, neurogenic inflammation, or cough in a subject in need thereof. The methods include administrating the antibody to the subject.

Abstract: A method of treating pruritus (itching) in a subject in need thereof is carried out by administering the subject an active agent in a treatment effective amount, wherein the active agent is a superoxide dismuate (SOD) mimetic. The SOD mimetic can be a complex of a metal (e.g., manganese) and an organic ligand, with suitable organic ligands including porphyrins, polyamines, salens, nitroxides, and fullerenes. Compositions for carrying out such methods are also described.

Abstract: A method of treating pruritus (itching) in a subject in need thereof is carried out by administering the subject an active agent in a treatment effective amount, wherein the active agent is a superoxide dismuate (SOD) mimetic. The SOD mimetic can be a complex of a metal (e.g., manganese) and an organic ligand, with suitable organic ligands including porphyrins, polyamines, salens, nitroxides, and fullerenes. Compositions for carrying out such methods are also described.